Published in AIDS Weekly, June 5th, 2006
The assay is a diagnostic tool to show tropism - the path taken by the virus to access human CD4 cells.
Tropism information is intended to help identify patients who are most likely to respond to a class of investigational drugs known as CCR5 antagonists. CCR5 antagonists are designed to block viral cell entry through the CCR5 coreceptor. Studies have shown that 80-85% of people newly diagnosed with HIV and previously untreated with HIV therapy have dominant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.